ライフサイエンスコーパス: plasmablastic

1 re or unrecognized lymphoma subtypes such as plasmablastic and primary effusion lymphomas.

2 of high-grade/anaplastic, intermediate-grade/plasmablastic, and low-grade/plasmacytic cases with simi

3 Thus, ALK-positive plasmablastic B-cell lymphomas are more heterogeneous at

4 ene expression profile of PEL was defined as plasmablastic because it showed features of both immunob

5 In the multivariate analysis, plasmablastic classification was the most powerful progn

6 wed bone marrow aspirate slides to determine plasmablastic classification.

7 ABC-DLBCL exhibits plasmablastic features and is characterized by aberranci

8 ls carry the stigmata of B lymphocytes, with plasmablastic features.

9 tiological agent of Kaposi sarcoma (KS), the plasmablastic form of multicentric Castleman's disease,

10 tiological agent of Kaposi sarcoma (KS), the plasmablastic form of multicentric Castleman's disease,

11 diseases, primary effusion lymphoma and the plasmablastic form of multicentric Castleman's disease.

12 Bcl-xl/Myc tumors are similar to a subset of plasmablastic human myelomas and provide insight into th

13 ranodal marginal zone lymphoma (n = 2, 11%), plasmablastic lymphoma (n = 1, 6%), and unspecified non-

14 ffuse large B-cell lymphoma (DLBCL; n = 61), plasmablastic lymphoma (n = 15), primary effusion lympho

15 Plasmablastic lymphoma (PBL) is a rare and aggressive no

16 Plasmablastic lymphoma (PBL) is an aggressive lymphoma c

17 Plasmablastic lymphoma (PBL) represents a rare and aggre

18 MHC II and plasma cell markers in DLBCL and plasmablastic lymphoma (PBL).

19 Plasmablastic lymphoma associated with MCD is a new dise

20 tt lymphoma, primary effusion lymphomas, and plasmablastic lymphoma of the oral cavity remain stable,

21 Furthermore, we show that the frank plasmablastic lymphoma that develops in patients with th

22 ay fill this niche for the treatment of PEL, plasmablastic lymphoma, MM, and other ADK-expressing can

23 Castleman disease (MCD), and MCD-associated plasmablastic lymphoma.

24 ollicles but may form microlymphoma or frank plasmablastic lymphoma.

25 terogeneity of primary DLBCL and 1 that is a plasmablastic lymphoma.

26 sly, we reported that the K1 protein induced plasmablastic lymphomas in K1 transgenic mice, and that

27 phomas to monoclonal microlymphoma and frank plasmablastic lymphomas in MCD patients.

28 age, a small number of B-lineage tumors with plasmablastic morphology and expression of the full-leng

29 Tumors have a plasmablastic morphology and variable expression of CD13

30 ion was significantly worse in patients with plasmablastic morphology compared with those without (me

31 ficantly greater proportion of patients with plasmablastic morphology had abnormal cytogenetics compa

32 Plasmablastic morphology is a powerful independent predi

33 Plasmablastic morphology was considered to be present (p

34 eatures, such as lack of expression of CD20, plasmablastic morphology, and clinical course characteri

35 Each had plasmablastic morphology, showed immunoglobulin A restri

36 ndices, beta2-microglobulin, hemoglobin, and plasmablastic morphology.

37 e also identified three risk groups based on plasmablastic morphology: plasma-cell labeling index, la

38 HIV-associated plasmablastic multicentric Castleman disease is an incre

39 si's sarcoma, primary effusion lymphoma, and plasmablastic multicentric Castleman's disease.

40 tic morphology was considered to be present (plasmablastic myeloma) when 2% or more plasmablasts were

41 We studied the prognostic significance of plasmablastic (PB) multiple myeloma (MM) in Eastern Coop

42 ted with B-cell growth transformation, had a plasmablastic phenotype, and frequently expressed the pr

43 zed in the spleen and PerC and had a B1-like/plasmablastic phenotype.

44 TIMP-1 expression in tumors with plasmacytic/plasmablastic phenotypes, including multiple myelomas.

45 Plasmablastic plasmacytomas from NFS.V(+) and SJL-beta2M

46 enes expressed by the most prevalent tumors, plasmablastic plasmacytomas, showed them to be most clos

47 d local therapy were not sufficient to treat plasmablastic posttransplant lymphoma even in localized

48 Plasmablastic posttransplant lymphoma is a rare subtype

49 Eight cases of plasmablastic posttransplant lymphoma were reported to t

50 gulation, indicating an arrested plasmacytic/plasmablastic stage of differentiation.

51 ng heterogeneity of the preplasmablastic and plasmablastic stages.

52 Plasmablastic tumors seemed to develop in an inflammator

53 nt factor in the pathogenesis of plasmacytic/plasmablastic tumors.

54 lymphoma that develops in patients with this plasmablastic variant of MCD is also positive for HHV-8

55 nt for two KSHV-associated malignancies, the plasmablastic variant of multicentric Castleman's diseas

56 ies, primary effusion lymphoma (PEL) and the plasmablastic variant of multicentric Castleman's diseas